Full-Time

Plant Manager

Integra LifeSciences

Integra LifeSciences

1,001-5,000 employees

Regenerative medicine, surgical devices provider

Compensation Overview

$125.3k - $172.5k/yr

+ Bonus + Commission + Equity

Irvine, CA, USA

In Person

On-site at Irvine facility in California.

Category
Operations & Logistics (1)
Required Skills
Six Sigma

Get referred to Integra LifeSciences

See people who can refer or advise you

Requirements
  • Engineering or Technical degree with 8+ years of experience leading a team (direct reports or projects) or equivalent education and years of management experience
  • Master degree with 5+ years of experience leading a team (direct reports or projects) or equivalent education and years of management experience
  • Demonstrate excellent organizational and English communication skills (oral & written)
  • Financial acumen relating to operations profit & loss (P&L) items
  • Proficiency in MS Office Suite and statistical analysis software
  • Experience in regulated environment; medical device or pharma preferred
  • Familiarity with health, safety, and environmental regulations related to manufacturing
  • Self-motivated team player with ability to work independently and collaboratively across all levels of the organization
Responsibilities
  • Responsible for ensuring the safety of all colleagues and fostering a culture of safety and compliance
  • Ensure environmental, health, and safety programs are compliant, effective, and continuously improving
  • Ensure accident, near miss, and incident events are managed appropriately and timely, teams are trained appropriately, and proper housekeeping is maintained
  • Foster a culture of colleague engagement thru positive leadership, recognition, career development, accountability, feedback, continuous improvement, and engagement activities
  • Lead the site in the continual pursuit of a stronger quality culture and a robust quality management system and ensure site's quality standards compliance as defined by Integra’s SOPs, GMP, Global Quality Standards, local and procedures, etc
  • Partner with Quality Assurance and Regulatory Affairs to ensure full compliance with applicable standards (FDA QSR, GMP, ISO 13485, etc)
  • Ensures robust defect processing including root cause and sustainable remediations
  • Ensure operations remain in controlled and validated state (IQOQPQTMV) and is full compliance with all local regulatory QMS procedures
  • Foster a continuous improvement culture to advance operational excellence and ensure sustained improvements in manufacturing reliability, throughput, and cost effectiveness
  • Develop strategies and plans to meet/beat site productivity and service targets leveraging lean six sigma tools and techniques (5S, Kaizen, Value Stream Mapping, Kanban, Standard Work. OEE) to reduce waste and improve operational efficiency
  • Lead the site as Value Stream Manager, driving end-to-end flow from suppliers through manufacturing to shipment; chair value stream daily/weekly tier meetings; own and improve SQDC metrics (safety, quality, delivery, cost); and align cross-functional teams (operations, engineering, quality, supply chain) on priorities, problem solving, and execution
  • Fully accountable to site’s financial performance and budget management, including oversight of headcount, operational expenses, and capital investments
  • Develop strategies and plans to meet both short term attainment and fulfillment plans as well as long term capacity plans aligning to enterprise objectives while maintaining flexibility
  • Complete other job-related duties as assigned
Desired Qualifications
  • Experience in regulated environment; medical device or pharma preferred

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-quarter 2026 beat and raised guidance restored investor confidence.
  • Codman Specialty Surgical concentration makes operational improvement highly leveraged.
  • Recent CEO appointment supports a clearer turnaround execution plan.

What critics are saying

  • Codman franchise concentration exposes earnings to neurosurgery share loss.
  • FDA or quality actions can halt multiple regulated product lines simultaneously.
  • Acquisition integration missteps can dilute margins and disrupt distribution channels.

What makes Integra LifeSciences unique

  • Founded in 1989 around regenerative medicine and artificial skin.
  • Strong neurosurgery portfolio spanning dural repair, CSF management, and cranial stabilization.
  • Cross-sells collagen-based wound and nerve repair products across hospital channels.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Feb 26th, 2026
Integra LifeSciences sees 0.7% organic revenue decline in 2025, guides to $1.66B–1.7B for 2026

Integra LifeSciences reported Q4 revenue of $435 million and adjusted earnings per share above guidance midpoint, but faces headwinds in 2025. Full-year revenue reached $1.635 billion with 0.7% organic decline, whilst gross margin fell 260 basis points to 61.9% due to tariffs, quality remediation and supply constraints. For 2026, the company guided revenue of $1.66 billion to $1.7 billion and adjusted EPS of $2.30 to $2.40, excluding potential new tariff impacts. Management expects operating cash flow exceeding $200 million and plans to reduce leverage from 4.5 times to 2.5–3.5 times by year-end. The company highlighted operational improvements including a new operating model, supply-chain resilience and early relaunches of PriMatrix and DuraRepair. A Braintree facility launching by June should support SurgiMend's Q4 2026 return.

Yahoo Finance
Feb 26th, 2026
Integra LifeSciences shares fall 3.5% on weak Q1 revenue forecast despite Q4 beat

Integra LifeSciences shares fell 3.5% after the medical device company issued weak revenue guidance for the first quarter and reported a significant drop in profitability. The company forecast first-quarter revenue of $382.5 million, 2.8% below analyst expectations. Whilst fourth-quarter revenue of $434.9 million and adjusted earnings per share of $0.83 beat expectations, underlying metrics showed deterioration. Revenue declined 1.7% year-over-year, operating margin fell sharply to 5.3% from 14.5% the previous year, and free cash flow was negative $5.4 million compared to positive $21.14 million a year ago. The combination of weak outlook and deteriorating profitability overshadowed the headline beats. Shares are down 6.9% year-to-date and trading 53.3% below their 52-week high.

Yahoo Finance
Feb 26th, 2026
Integra LifeSciences Q4 sales beat estimates but Q1 guidance misses by 2.8%

Integra LifeSciences reported Q4 2025 revenue of $434.9 million, beating analyst estimates by 1% but declining 1.7% year on year. The medical device company's adjusted earnings per share of $0.83 exceeded expectations by 3.7%. However, the company's Q1 2026 revenue guidance of $382.5 million fell 2.8% below analyst estimates. Operating margin dropped to 5.3% from 14.5% in the prior year quarter, whilst free cash flow turned negative at -$5.4 million. Founded in 1989, Integra develops medical technologies for neurosurgery, wound care and surgical reconstruction. The company has struggled with tepid growth, recording just 3.6% compound annual revenue growth over five years. Its organic revenue rose 2.5% year on year in the quarter.

Yahoo Finance
Feb 25th, 2026
Integra LifeSciences to report Q4 earnings tomorrow amid 2.7% revenue decline forecast

Medical device company Integra LifeSciences will report earnings tomorrow, with analysts expecting revenue to decline 2.7% year on year, reversing an 11.5% increase from the same quarter last year. The company missed revenue expectations last quarter, reporting $402.1 million in revenues, up 5.6% year on year. It also significantly missed revenue guidance for the following quarter. Integra has missed Wall Street's revenue estimates multiple times over the past two years. Analysts have generally reconfirmed their estimates over the last 30 days. Integra's shares are up 5.7% over the past month, outperforming the healthcare equipment segment's 1.9% decline. The stock currently trades at $11.70 against an average analyst price target of $15.50.

DECCO, Inc.
Nov 13th, 2025
DECCO Recognized for "Excellence in Construction"

DECCO recognized for "Excellence in Construction" WOBURN, MA - The Massachusetts Chapter of Associated Builders and Contractors (ABC MA) congratulates DECCO for earning an Eagle Award at the 33rd annual Excellence in Construction Awards for their outstanding work on Integra Life Sciences' Project Revere. Nearly 250 ABC members gathered at the Four Points by Sheraton Hotel in Norwood on November 6th to recognize and celebrate the very best construction projects their companies have to offer. This year's applicant pool was particularly competitive, with each winner selected for the high standards of craftsmanship, safety and quality delivered by talented merit shop workers using the efficient merit shop approach. "We are proud to recognize the outstanding work of our member contractors through the ABC Excellence in Construction Awards," said ABC MA President Greg Beeman. "The winning contractors maintained a constant focus on meeting their clients' needs and set a high bar for craftsmanship, quality and safety." The Eagle Award DECCO won for Project Revere is the pinnacle of achievement. It recognizes overall excellence in project execution, craftsmanship, safety, innovative elements and challenges, and client satisfaction. The Massachusetts Chapter of Associated Builders and Contractors is the largest construction trade association in the Commonwealth, representing nearly 500 local general contractor, subcontractor, supplier and associate members that employ over 20,000 workers throughout Massachusetts.